358 related articles for article (PubMed ID: 30350370)
1. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.
McCart Reed AE; Kalaw E; Nones K; Bettington M; Lim M; Bennett J; Johnstone K; Kutasovic JR; Saunus JM; Kazakoff S; Xu Q; Wood S; Holmes O; Leonard C; Reid LE; Black D; Niland C; Ferguson K; Gresshoff I; Raghavendra A; Harvey K; Cooper C; Liu C; Kalinowski L; Reid AS; Davidson M; Pearson JV; Pathmanathan N; Tse G; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox SB; O'Toole SA; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2019 Feb; 247(2):214-227. PubMed ID: 30350370
[TBL] [Abstract][Full Text] [Related]
2. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
[No Abstract] [Full Text] [Related]
3. Mixed ductal-lobular carcinomas: evidence for progression from ductal to lobular morphology.
McCart Reed AE; Kutasovic JR; Nones K; Saunus JM; Da Silva L; Newell F; Kazakoff S; Melville L; Jayanthan J; Vargas AC; Reid LE; Beesley J; Chen XQ; Patch AM; Clouston D; Porter A; Evans E; Pearson JV; Chenevix-Trench G; Cummings MC; Waddell N; Lakhani SR; Simpson PT
J Pathol; 2018 Apr; 244(4):460-468. PubMed ID: 29344954
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A loss and PIK3CA mutation in myoepithelial-like metaplastic breast cancer.
Bartels S; van Luttikhuizen JL; Christgen M; Mägel L; Luft A; Hänzelmann S; Lehmann U; Schlegelberger B; Leo F; Steinemann D; Kreipe H
J Pathol; 2018 Jul; 245(3):373-383. PubMed ID: 29708279
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
Hennessy BT; Gonzalez-Angulo AM; Stemke-Hale K; Gilcrease MZ; Krishnamurthy S; Lee JS; Fridlyand J; Sahin A; Agarwal R; Joy C; Liu W; Stivers D; Baggerly K; Carey M; Lluch A; Monteagudo C; He X; Weigman V; Fan C; Palazzo J; Hortobagyi GN; Nolden LK; Wang NJ; Valero V; Gray JW; Perou CM; Mills GB
Cancer Res; 2009 May; 69(10):4116-24. PubMed ID: 19435916
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
7. Metaplastic Breast Cancer: Molecular Typing and Identification of Potential Targeted Therapies at a Single Institution.
Edenfield J; Schammel C; Collins J; Schammel D; Edenfield WJ
Clin Breast Cancer; 2017 Feb; 17(1):e1-e10. PubMed ID: 27568101
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of snail in metaplastic breast carcinoma.
Nassar A; Sookhan N; Santisteban M; Bryant SC; Boughey JC; Giorgadze T; Degnim A
Diagn Pathol; 2010 Nov; 5():76. PubMed ID: 21110878
[TBL] [Abstract][Full Text] [Related]
9. Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition.
Zhang Y; Toy KA; Kleer CG
Mod Pathol; 2012 Feb; 25(2):178-84. PubMed ID: 22080057
[TBL] [Abstract][Full Text] [Related]
10. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.
Akcakanat A; Zheng X; Cruz Pico CX; Kim TB; Chen K; Korkut A; Sahin A; Holla V; Tarco E; Singh G; Damodaran S; Mills GB; Gonzalez-Angulo AM; Meric-Bernstam F
Clin Cancer Res; 2021 Jun; 27(11):3243-3252. PubMed ID: 33782032
[TBL] [Abstract][Full Text] [Related]
11. Opposite Prognostic Impact of Single PTEN-loss and
Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer.
Leo F; Bartels S; Mägel L; Framke T; Büsche G; Jonigk D; Christgen M; Lehmann U; Kreipe H
Virchows Arch; 2016 Aug; 469(2):191-201. PubMed ID: 27220763
[TBL] [Abstract][Full Text] [Related]
13. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological features of metaplastic breast carcinoma.
Hasdemir OA; Tokgöz S; Köybaşıoğlu F; Karabacak H; Yücesoy C; İmamoğlu Gİ
Adv Clin Exp Med; 2018 Apr; 27(4):509-513. PubMed ID: 29558027
[TBL] [Abstract][Full Text] [Related]
15. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
16. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation.
Beca F; Sebastiao APM; Pareja F; Dessources K; Lozada JR; Geyer F; Selenica P; Zeizafoun N; Wen HY; Norton L; Brogi E; Weigelt B; Reis-Filho JS
Histopathology; 2020 Aug; 77(2):321-326. PubMed ID: 32043609
[TBL] [Abstract][Full Text] [Related]
18. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
[TBL] [Abstract][Full Text] [Related]
19. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.
Bataillon G; Fuhrmann L; Girard E; Menet E; Laé M; Capovilla M; Treilleux I; Arnould L; Penault-Llorca F; Rouzier R; Marchiò C; Bieche I; Vincent-Salomon A
Histopathology; 2018 Aug; 73(2):273-283. PubMed ID: 29537649
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
